2,644 Shares in Encompass Health Corporation (NYSE:EHC) Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC purchased a new position in Encompass Health Corporation (NYSE:EHC - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,644 shares of the company's stock, valued at approximately $268,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EHC. Colonial Trust Co SC purchased a new position in shares of Encompass Health in the fourth quarter worth approximately $29,000. Transce3nd LLC acquired a new position in Encompass Health in the 4th quarter worth approximately $40,000. CBIZ Investment Advisory Services LLC boosted its position in shares of Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares during the period. Signaturefd LLC raised its position in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after buying an additional 125 shares during the period. Finally, Johnson Financial Group Inc. purchased a new stake in Encompass Health in the 4th quarter worth about $72,000. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Price Performance

Shares of EHC traded up $0.16 during mid-day trading on Friday, reaching $119.04. The company had a trading volume of 400,752 shares, compared to its average volume of 703,217. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06. The company has a market capitalization of $12.00 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.42 and a beta of 0.88. Encompass Health Corporation has a twelve month low of $82.74 and a twelve month high of $123.13. The company's 50-day moving average is $119.39 and its 200-day moving average is $105.37.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.12 earnings per share. On average, equities analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio (DPR) is currently 14.05%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EHC. Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target on the stock in a research note on Thursday, June 5th. Royal Bank Of Canada lifted their price objective on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. UBS Group upped their price target on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Finally, Truist Financial restated a "buy" rating and issued a $135.00 target price (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $127.00.

Insider Transactions at Encompass Health

In related news, insider Elissa Joy Charbonneau sold 4,279 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the sale, the insider owned 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark J. Tarr sold 118,384 shares of the firm's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer directly owned 527,070 shares of the company's stock, valued at approximately $64,054,817.10. This trade represents a 18.34% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is currently owned by company insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.